Literature DB >> 1834145

Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intramuscular doses.

D J Nichols1, A Bye, E Novak.   

Abstract

The pharmacokinetics of trospectomycin (75-1000 mg free base equivalents) were studied in 128 healthy males (eight per dose group), after a 20 min intravenous (i.v.) infusion and intramuscular (i.m.) injection of trospectomycin sulphate. The concentrations of trospectomycin in serum were described by bi- or tri-exponential disposition functions indicating an initial half-life of 1.1-1.4 h for the i.v. dose and 1.6-2.1 h for the i.m. dose and terminal half-lives of over 15 h. Most of the drug was eliminated rapidly (mean residence time 5-12 h). The distribution volume was 59-112% of body weight and clearance was 112-152 ml min-1. The absorption into blood after i.m. dosing was rapid. The area under the concentration-time curve and maximum concentration values were linearly related to dose. Serum drug concentrations fell below the minimum inhibitory concentration values for a variety of organisms by 8-12 h, which indicates that two or three times daily dosing would be appropriate. However, the long terminal half-life suggests that significant accumulation is likely in some tissues with an 8 h dose interval and this may prolong the action of trospectomycin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834145      PMCID: PMC1368455          DOI: 10.1111/j.1365-2125.1991.tb03893.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate.

Authors:  J W Cox; R G Ulrich; M A Wynalda; R McKenna; E R Larsen; L C Ginsberg; D E Epps
Journal:  Biochem Pharmacol       Date:  1989-10-15       Impact factor: 5.858

2.  Hepatic changes produced by 30-day administration of a novel aminocyclitol antibiotic, trospectomycin sulfate, to laboratory animals.

Authors:  R G Ulrich; D K Petrella; E R Larsen; J W Cox; C T Cramer; R C Piper; J E Gray
Journal:  Fundam Appl Toxicol       Date:  1990-01

3.  Distribution and disposition of trospectomycin sulfate in the in vivo rat, perfused rat liver, and cultured rat hepatocytes.

Authors:  J W Cox; L G Dring; L C Ginsberg; P G Larson; D A Constable; R G Ulrich
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

4.  Trospectomycin, a novel spectinomycin analogue: antibacterial activity and preliminary human pharmacokinetics.

Authors:  G E Zurenko; C W Ford; E Novak
Journal:  Drugs Exp Clin Res       Date:  1988
  4 in total
  1 in total

1.  Trospectomycin in acute pelvic inflammatory disease: a preliminary report.

Authors:  A Chatwani; V Dandalou; O Harmanli; P Nyirjesy
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.